Table 9

Longitudinal studies on serum CA125 levels and survival in ovarian cancer

First Author, Year, Study Place

Data Collection

Study Design

Sample Size

Groups being Compared

RR/HR, (95% CI), P-Value

Conclusion

Variables Adjusted for

Riedinger JM, 2007, France [47]

1988 to 1996

Multicentric study

494

≥ 75% decrease, < 75% decrease or increase

Univariate- 1.92 (1.34--2.74), < 0.0001 3.08 (2.10--4.50), < 0.0001

Multivariate-0.90 (0.59--1.39), NS

0.97 (0.59--1.59), NS

The CA125 change after first course of CT was independent prognostic factors for both achievement of pathological complete response and overall survival.

Age, Histology

FIGO stage, Residual tumor

Markman M, 2006, USA [37]

NA

Longitudinal study

291

I > 100, ≤ 35 u/ml

II 36--99, ≤ 35 u/ml

III > 100, 36--99 u/ml

I - 3.0 (1.7--8.6), 0.0001

II - 1.6 (0.9--2.8), 0.09

III-1.8 (1.0--3.5), 0.07

While pretreatment CA125 values did not correlate with survival, the concentration of CA125 8 weeks after initiation of therapy was a powerful independent prognostic factor.

Age, performance status, disease stage, measurable disease, treatment, tumor necrosis, stromal sclerosis

Gupta and Lis Journal of Ovarian Research 2009 2:13   doi:10.1186/1757-2215-2-13